Login / Signup

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.

Bindu ChamarthiJ Michael GazianoLawrence BlondeAaron I VinikRichard E ScrantonMichael EzrokhiDean RuttyAnthony H Cincotta
Published in: Journal of diabetes research (2015)
Bromocriptine-QR therapy slowed the progression of CVD and metabolic disease in T2DM subjects in good glycemic control.
Keyphrases
  • glycemic control
  • type diabetes
  • cardiovascular disease
  • blood glucose
  • weight loss
  • insulin resistance
  • metabolic syndrome
  • cardiovascular risk factors
  • cell therapy
  • bone marrow
  • replacement therapy